This blog explores how clinical research leaders are navigating post-Covid uncertainty, shifting buyer expectations, and the growing need for authenticity, trust, and AI-driven value.
The Quality Issue – April 2025
From Vancouver to London, this edition highlights must-attend RBQM events that offer fresh insights, regulatory updates, and real-world strategies to elevate your clinical trial oversight.
SCDM – April 2025
We’re heading to Brussels for SCDM 2025 EMEA! Visit TRI at Booth 21 to discover how our reimagined OPRA-CM platform is transforming centralized monitoring and driving RBQM success.
The Quality Issue – February 2025
In this edition, we reflect on two standout events, RBQM Summit and SCOPE 2025.
The Quality Issue – January 2025
We spotlight major developments in clinical research, from new FDA biopsy guidance and the EU’s CTIS transition deadline.
Dose Optimization in Oncology: Advancing Clinical Trial Quality
The FDA’s latest guidance on dose optimization marks a pivotal shift in oncology drug development.
TRI Joins Veeva’s Product Partner Program
TRI has joined Veeva’s Product Partner Program, integrating OPRA with Vault EDC to deliver faster, smarter RBQM.
RBQDM Takes Center Stage at SCDM 2024
At SCDM 2024, RB-CDM took center stage, signalling a shift toward more strategic, risk-focused data management.
The Quality Issue – September 2024
This month’s Quality Issue highlights FDA guidance on RCTs and decentralized trials, and invites you to RBQM Ops 2024.
Inside the FDA’s Radical New Plan
The FDA’s latest draft guidance could reshape clinical research by embedding RCTs into everyday healthcare.